Andrea G. Manzanera
YOU?
Author Swipe
View article: 513 Advanced analytics identify a differential immune response to CAN-2409+valacyclovir in non-squamous vs squamous NSCLC, linked to improved survival in patients with progressive ICI-refractory NSCLC
513 Advanced analytics identify a differential immune response to CAN-2409+valacyclovir in non-squamous vs squamous NSCLC, linked to improved survival in patients with progressive ICI-refractory NSCLC Open
View article: Neoadjuvant CAN-2409 plus Prodrug in Combination with Standard of Care Chemoradiation forBorderline Resectable Pancreatic Adenocarcinoma
Neoadjuvant CAN-2409 plus Prodrug in Combination with Standard of Care Chemoradiation forBorderline Resectable Pancreatic Adenocarcinoma Open
Pancreatic ductal adenocarcinoma (PDAC) remains a deadly form of cancer because of its cold and immunosuppressive tumor microenvironment. A previous phase 1b clinical trial showed that treatment with CAN-2409 plus valacyclovir induced a si…
View article: Clinical trial links oncolytic immunoactivation to survival in glioblastoma
Clinical trial links oncolytic immunoactivation to survival in glioblastoma Open
View article: 1477 First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma
1477 First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma Open
Background High-grade glioma (HGG) is characterized by a highly immunosuppressive tumor microenvironment and poor prognosis. Limited advances have been made in HGG standard of care (SoC) treatment, with immunotherapy failures reported in t…
View article: CTIM-09. ENRICHED TCR/BCR VDJ REARRANGEMENTS CORRELATE WITH MRI AND SURVIVAL OUTCOMES IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA TREATED WITH CAN-3110
CTIM-09. ENRICHED TCR/BCR VDJ REARRANGEMENTS CORRELATE WITH MRI AND SURVIVAL OUTCOMES IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA TREATED WITH CAN-3110 Open
BACKGROUND CAN-3110 (rQNestin34.5v2) is an HSV-1 oncolytic viral immunotherapy with one copy of the inflammatory ICP34.5 gene under transcriptional control of the Nestin glioma-specific promoter. We completed a phase 1 sequential dose-esca…
View article: CTIM-13. PHASE 1 CLINICAL TRIAL OF ONCOLYTIC VIRAL IMMUNOTHERAPY WITH CAN-2409 + VALACYCLOVIR IN COMBINATION WITH NIVOLUMAB AND STANDARD OF CARE (SOC) IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA (HGG)
CTIM-13. PHASE 1 CLINICAL TRIAL OF ONCOLYTIC VIRAL IMMUNOTHERAPY WITH CAN-2409 + VALACYCLOVIR IN COMBINATION WITH NIVOLUMAB AND STANDARD OF CARE (SOC) IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA (HGG) Open
BACKGROUND CAN-2409 is a replication-deficient adenovirus that delivers HSV thymidine kinase to cancer cells, resulting in local conversion of orally administered valacyclovir into a toxic metabolite. Previously, a phase 1b/2 clinical tria…
View article: Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity
Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity Open
Gene-mediated cytotoxic immunotherapy (GMCI) is an immuno-oncology approach involving local delivery of a replication-deficient adenovirus expressing herpes simplex thymidine kinase (AdV-tk) followed by anti-herpetic prodrug activation tha…
View article: Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma
Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma Open
ClinicalTrials.gov NCT00634231.
View article: Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion
Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion Open
View article: EPT-14PHASE I STUDY OF GENE MEDIATED CYTOTOXIC IMMUNOTHERAPY WITH AdV-tk AS ADJUVANT TO SURGERY AND RADIATION THERAPY FOR PEDIATRIC MALIGNANT GLIOMA AND RECURRENT EPENDYMOMA
EPT-14PHASE I STUDY OF GENE MEDIATED CYTOTOXIC IMMUNOTHERAPY WITH AdV-tk AS ADJUVANT TO SURGERY AND RADIATION THERAPY FOR PEDIATRIC MALIGNANT GLIOMA AND RECURRENT EPENDYMOMA Open
View article: Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma
Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma Open
ClinicalTrials.gov NCT00589875.
View article: IMCT-02PHASE II MULTICENTER STUDY OF GENE MEDIATED CYTOTOXIC IMMUNOTHERAPY AS ADJUVANT TO SURGICAL RESECTION FOR NEWLY DIAGNOSED MALIGNANT GLIOMA
IMCT-02PHASE II MULTICENTER STUDY OF GENE MEDIATED CYTOTOXIC IMMUNOTHERAPY AS ADJUVANT TO SURGICAL RESECTION FOR NEWLY DIAGNOSED MALIGNANT GLIOMA Open
View article: Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma
Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma Open